Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. regarding possible recovery of investor losses under federal securities laws following a significant stock price decline after trial results announcement [1][4]. Group 1: Investigation Details - The investigation focuses on Ocular's executive officers and their compliance with federal securities laws [1][4]. - Ocular announced topline results from its SOL-1 Phase 3 trial on February 17, 2026, revealing that 74% of patients maintained vision at nine months, 66% at twelve months, and approximately 69% were rescue-free at 52 weeks [3]. - Following the announcement, Ocular's stock price declined approximately 27% [3]. Group 2: Law Firm Background - Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with multiple offices across the United States, representing both individual and institutional investors [5]. - The firm has been ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services in 2024, having recovered approximately $90.725 million for clients in cases where it served as lead or co-lead counsel [6].